MARKET

NMRA

NMRA

Neumora Therapeutics Inc
NASDAQ
2.220
-0.110
-4.72%
After Hours: 2.250 +0.03 +1.35% 19:20 01/09 EST
OPEN
2.360
PREV CLOSE
2.330
HIGH
2.570
LOW
2.210
VOLUME
2.16M
TURNOVER
--
52 WEEK HIGH
3.250
52 WEEK LOW
0.6110
MARKET CAP
377.26M
P/E (TTM)
-1.5172
1D
5D
1M
3M
1Y
5Y
1D
Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances
NASDAQ · 1d ago
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
Benzinga · 3d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 3d ago
Neumora Therapeutics price target raised to $6 from $5 at Mizuho
TipRanks · 4d ago
J.P. Morgan Remains a Sell on Neumora Therapeutics, Inc. (NMRA)
TipRanks · 4d ago
NEUMORA THERAPEUTICS INC <NMRA.O>: MIZUHO RAISES TARGET PRICE TO $6 FROM $5
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Costco, Topgolf Callaway Brands
Reuters · 4d ago
Neumora's Alzheimer's Agitation Drug Shows Early Promise
Benzinga · 4d ago
More
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Webull offers Neumora Therapeutics Inc stock information, including NASDAQ: NMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NMRA stock methods without spending real money on the virtual paper trading platform.